Skip to main content

People in the News: Craig Venter, Ted Goldstein, Jeffrey Busch, John Brugmann, Mick Ruxin, More

Craig Venter

Craig Venter announced that he is retiring from Human Longevity, the company he cofounded and where he serves as chairman and CEO. Venter said in a tweet that he will be returning to the J. Craig Venter Institute, which he founded in 2006, "to continue my work."


Ted Goldstein

Precision medicine informatics company GNS Healthcare has named bioinformatician and biomedical engineer Ted Goldstein to its strategic advisory board. Goldstein, who serves as the scientific program director of computational health at the University of California, San Francisco, is leading the development of a machine learning-based comprehensive cancer diagnosis and treatment model for the university. He previously served as vice president of developer tools at Apple and as an e-commerce hardware developer for Sun Microsystems.


Jeffrey Busch, John Brugmann, Mick Ruxin

Avant Diagnostics has appointed Jeffrey Busch as chairman of its board of directors and John Brugmann as a director on the board. In addition, Mick Ruxin has joined the firm as CEO, resident, and board member.


For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.